---
figid: PMC3718392__nihms481471f2
figtitle: Targeting of PI3K/mTORC1 signaling in hamartoma syndromes
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Saccharomyces cerevisiae
- Drosophila melanogaster
pmcid: PMC3718392
filename: nihms481471f2.jpg
figlink: /pmc/articles/PMC3718392/figure/F2/
number: F2
caption: Potential targeting of PI3K/mTORC1 signaling in hamartoma syndromes. Germline
  mutations of PTEN, LKB1, TSC1 and TSC2 genes lead to upregulation of PI3K/mTORC1
  signaling and are associated with spectrum of hamartoma syndromes (Light blue boxes).
  Blue coloring indicate tumor suppressor proteins, negatively regulating mTORC1 signaling.
  Germline mutations of PTEN is associated with Cowden syndrome (CS), Lhermitte-Duclos
  disease (LDD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syndrome (PS),
  and Proteus-Like syndrome; germline mutations of LKB1 is associated with Peutz-Jeghers
  syndrome (PJS), TSC1 or TSC2 mutations is associated with Tuberous Sclerosis Complex
  (TSC) and Lymphangioleiomyomatosis (LAM). Pink coloring indicate inhibitors of PI3K/
  mTORC1 signaling pathway, which may have promising therapeutic effects for treatment
  of hamartoma syndromes. Rapamycin and it analogs CCI-779, RAD001 and AP23573 are
  to inhibit mTORC1; PI-103, SF11206 and ZSTK474 are pan-PI3K inhibitors; NVP-BEZ235
  and XL765 simultaniously target mTORC1 and PI3K.
papertitle: PI3K/mTORC1 activation in hamartoma syndromes.
reftext: Vera P. Krymskaya, et al. Cell Cycle. ;8(3):403-413.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8900956
figid_alias: PMC3718392__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Mus musculus
- Homo sapiens
- Rattus norvegicus
redirect_from: /figures/PMC3718392__F2
ndex: dbfce6b0-deb6-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3718392__nihms481471f2.html
  '@type': Dataset
  description: Potential targeting of PI3K/mTORC1 signaling in hamartoma syndromes.
    Germline mutations of PTEN, LKB1, TSC1 and TSC2 genes lead to upregulation of
    PI3K/mTORC1 signaling and are associated with spectrum of hamartoma syndromes
    (Light blue boxes). Blue coloring indicate tumor suppressor proteins, negatively
    regulating mTORC1 signaling. Germline mutations of PTEN is associated with Cowden
    syndrome (CS), Lhermitte-Duclos disease (LDD), Bannayan-Riley-Ruvalcaba syndrome
    (BRRS), Proteus syndrome (PS), and Proteus-Like syndrome; germline mutations of
    LKB1 is associated with Peutz-Jeghers syndrome (PJS), TSC1 or TSC2 mutations is
    associated with Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis
    (LAM). Pink coloring indicate inhibitors of PI3K/ mTORC1 signaling pathway, which
    may have promising therapeutic effects for treatment of hamartoma syndromes. Rapamycin
    and it analogs CCI-779, RAD001 and AP23573 are to inhibit mTORC1; PI-103, SF11206
    and ZSTK474 are pan-PI3K inhibitors; NVP-BEZ235 and XL765 simultaniously target
    mTORC1 and PI3K.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Pten
  - cs
  - ps
  - pls
  - Akt
  - Tsc1
  - Crtc
  - gig
  - Rheb
  - Tsc
  - Lam
  - LanA
  - S6k
  - Thor
  - Lkb1
  - SNF4Agamma
  - AMPKalpha
  - Pik3r1
  - Cs
  - Ps
  - Akt1
  - Tsc2
  - Slc12a3
  - Tsc22d1
  - Lsamp
  - Rps6kb1
  - Eif4ebp1
  - Stk11
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - CS
  - CTSC
  - AKT1
  - AKT2
  - AKT3
  - TSC1
  - CCL26
  - MTOR
  - RPTOR
  - TSC2
  - RHEB
  - RHEBP1
  - SLC12A3
  - TESC
  - RPS6KB1
  - EIF4EBP1
  - STK11
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - Pik3cg
  - Prkaa2
  - SF1126
  - NVP-BEZ235
  - Rapamycin
  - Cancer
---
